<DOC>
	<DOCNO>NCT00570635</DOCNO>
	<brief_summary>The purpose study evaluate clinical benefit KIT inhibitor XL820 subject advanced gastrointestinal stromal tumor ( GIST ) resistant intolerant Imatinib and/or Sunitinib .</brief_summary>
	<brief_title>A Phase 2 Study XL820 Adults With Advanced GIST Resistant Imatinib and/or Sunitinib</brief_title>
	<detailed_description />
	<mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
	<mesh_term>Gastrointestinal Neoplasms</mesh_term>
	<mesh_term>Digestive System Neoplasms</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>Patients metastatic locally advanced unresectable GIST intolerance disease progression follow prior treatment imatinib and/or sunitinib ECOG ( Eastern Cooperative Oncology Group ) performance status ≤2 Must measurable disease per RECIST ( Response Evaluation Criteria Solid Tumors ) Recovery toxicity prior therapy Common Terminology Criteria Adverse Events ( CTCAE ) v3.0 Grade ≤1 subject 's baseline status Adequate organ marrow function Sexually active subject ( male female ) must agree use accept method contraception course study 3 month follow discontinuation study drug . Female subject childbearing potential must negative pregnancy test enrollment . Therapy imatinib sunitinib within 14 day first dose study drug Chemotherapy , immunotherapy , target therapy , chemoembolization , investigational drug treatment GIST last dose imatinib sunitinib Anticoagulation warfarin coumarinrelated compound Radiation ≥25 % bone marrow within 28 day study entry Treatment investigational agent within 28 day first dose XL820 Known central nervous system metastasis Uncontrolled intercurrent illness Pregnancy breastfeed Active bacterial viral infection require systemic treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>GIST</keyword>
	<keyword>Gastrointestinal Cancer</keyword>
</DOC>